The Single-Cell Intracellular Proteome for intracellular signaling omics provides functional characterization of the signaling networks and resistance pathways of cancer cells for the development of improved treatments to combat therapeutic resistance.

Highly Multiplexed Analysis

Highly multiplexed phosphoprotein analysis at single-cell resolution

Functional Phenotyping

Functional Phenotyping targeting 500-1500 single cells per chip

Fully Automated

Fully automated, quick, and cost-efficient workflow

Human Tumor Signaling

P-IkBA, Cleaved PARP, P-Stat5, Alpha Tubulin, P-p44-42 MAPK, P-Stat3, P-Rb, P-NF-kB
p65, P-PRAS40, P-eIF4E, P-MEK1-2, P-S6 Ribosomal, P-p90RSK, P-Stat1, P-Met

Human Adaptive Immune (Coming Soon)

P-Akt, P-p53, P-PD1, P-LCK, P-CD3 zeta, P-Zap70, P-CCR7, P-CD28, P-41BB, P-MEK 1/2,
P-P44/42 MAPK (ERK1/2), P-Jak1, P-Jak2, P-AMPK, P-PI3K, P-mTOR, P-P21, P-LAT,
P-NF-kB p65, Alpha Tubulin

Intracellular Signaling Omics Characterizes Signaling Mechanisms Driving Resistance

IsoPlexis’ Single-Cell Intracellular Proteome solution was employed in the analysis of the resistance pathways of BRAFV600E M397 mutant melanoma cells treated with BRAF inhibitor (BRAFi). IsoPlexis’ technology revealed two distinct subpopulations of BRAFV600E M397 cells which followed different pathways to drug resistance and had different drug susceptibilities. This technology provided insights for researchers to identify effective combination therapies to combat this resistance.

Su et al. “Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line.” Nature Communications 11: 2345, 2020.

Product Specifications